Ventyx rises on completion of enrollment in two mid-stage trials

Ventyx Biosciences

07/06/2023 15:24

** Shares of drug developer Ventyx Biosciences Inc  VTYX.O 
rises 3.5% to $36.03
    ** Co completes patient enrollment in two mid-stage trials,
which are testing two different drug candidates to treat a bowel
disease called ulcerative colitis and itchy skin disease called
plaque psoriasis
    ** The ulcer study has 180 enrolled patients, while the
psoriasis trial has 200 patients
    ** Topline data from both trials expected in Q4 of 2023-
VTYX
    ** Stock up 9.8% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))